Overview
- An international phase 3 trial in metastatic pancreatic cancer found median overall survival of 13.2 months on daraxonrasib compared with 6.7 months on chemotherapy.
- The FDA placed the drug under accelerated review and allowed early access for some patients, with full results slated for presentation in Chicago this month and not yet peer-reviewed.
- Daraxonrasib blocks mutant KRAS, a driver in most pancreatic tumors long seen as unreachable, using a “molecular glue” design informed by a 2013 finding of a druggable pocket on the protein.
- The medicine is an oral pill taken three times a day and can cause diarrhea, fatigue, nausea, skin rashes, and painful skin lesions.
- The approach could widen options for KRAS-driven cancers and is spurring rival programs, while patients like California retiree Rhea Caras report extended time and steadier daily life on the drug.